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assessment (RA), which involves examining the intrinsic toxicity of 
an agent (hazard assessment) and comparing it with the anticipated 
human exposure to characterize the likelihood of adverse effects (risk 
characterization). Although this process is meant to integrate all data 
sources (human, environmental, in vivo, in vitro, in silico), in practice 
existing regulations of pharmaceutical and chemical substances con-
tinue to ask for sector-specific RAs, each of which has its own specific 
information requirements and uses different methods for the ultimate 
risk quantification. Although regulators often stress the primacy of 
human data, in practice their use is constrained by availability and 
lack of defined quality criteria. There have been some efforts in the 
past to develop frameworks for the use of human data (eg, from 
poison centers) for risk assessment purposes. However, these have 
had only limited success. More recently, integrated approaches have 
been developed using information from animal studies and human 
data based on mode of action and weight of evidence concepts. These 
approaches need to be tested and validated. Harmonized data col-
lection based on defined quality criteria is a precondition for better 
use of human data in risk assessment. It will only become a reality if 
existing networks of institutions such as poison control and clinical 
toxicology centers are being strengthened and, importantly, if they 
interact with regulatory decision makers on a regular basis. This 
will result in enhanced sharing of knowledge, build consensus, and 
facilitate clear, easily understood, transparent, and unambiguous inte-
grated RA procedures. Network initiatives such as the EU FP7 project 
HEROIC aim to contribute to the development of such harmonized 
approaches that meet the challenges of RA.
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Clinical pharmacology in Russia was established 13 years after the 
first World Health Organization (WHO) manifesto describing its 
duties was released. In 1983, it was defined as a separate educational 
discipline in medical universities. Starting from 1997, the medical 
specialty “clinical pharmacologist” was established, and its func-
tions were defined. It was built on the union of pharmacology and 
internal medicine, and that is why clinical pharmacology in Russia 
is characterized by close proximity to routine patient care. A clini-
cal pharmacologist in Russia should first receive training in internal 
medicine and then 2-year specialization in clinical pharmacology. 
The current main duties of clinical pharmacologists in Russia are 
defined by the ministerial laws released in 2003 and 2010, updated 
in 2012. According to these documents, clinical pharmacologists 
should see patients and be able to adjust treatment by taking into 
account various possible factors of individual response to medica-
tions. They should advise when necessary and interpret results of 
pharmacogenetic analyses; perform therapeutic drug monitoring and 
drug interaction analyses; and diagnose, register, and manage adverse 
drug reactions. Furthermore, clinical pharmacologists should manage 
quality control of medications used in their hospitals, participate in 
drug and therapeutics committees, develop and maintain a system of 
formulary lists of medications, perform drug utilization surveillance, 
participate in microbiology monitoring in relation to antibiotic utili-
zation, define economic feasibility of different medications use, and 
approve purchase of drugs according to the general hospital needs. 
They should also provide informational services to physicians and 
patients on various issues of rational drug use.
According to the current law, every medical institution should 
have a position of clinical pharmacologist; hospitals with > 500 
beds are advised to have a corresponding division. This provides 
grounds for active development of the specialty and improvement 
of educational programs. Some universities have courses of clini-
cal pharmacology included in the curriculum of other specialists. 
Since 2009, clinical pharmacologists in Russia are cooperating 
within the all-Russian “Association of Clinical Pharmacologists” 
comprising the vast majority or regions. The association is per-
forming important organizational, informational and expert func-
tions.
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Summary: To clarify the potential association between diabetes, 
related factors, treatments, and breast cancer risk, a series of meta-
analyses was carried out following PRISMA guidelines. For breast 
cancer at all ages, the risks obtained from prospective studies were: 
diabetes (SRR = 1.27 [95% CI, 1.16 to 1.39]); physical activity (SRR 
= 0.88 [0.85 to 0.92]); glycemic load (SRR = 1.05 [1.00 to 1.10]); 
glycemic index (SRR = 1.05 [1.00 to 1.09]); fasting glucose (SRR 
= 1.14 [0.94 to 1.37]); serum insulin (SRR = 1.11 [0.75 to 1.85]); 
c-peptide (SRR = 1.00 [0.69 to 1.46]), and adiponectin (SRR = 1.16 
[0.93 to 1.46]). An increase of 5 units in BMI was associated with 
postmenopausal breast cancer (SRR = 1.12 [95% CI, 1.08 to 1.16]) 
but not at premenopausal ages (SRR = 0.83 [95% CI, 0.72 to 0.95]). 
Serum insulin and c-peptide were associated with breast cancer at 
postmenopausal ages but not at premenopausal. For IGF-1, Hodge’s 
standardized mean difference (HSMD) was calculated, and there was 
no significant association with breast cancer (HSMD = 0.026 [95% 
CI, –0.031 to 0.084]).
The SRR for breast cancer among users of insulin glargine was 
1.08 (0.98 to 1.20) and was 0.92 (0.32 to 2.65) when restricted to 
randomized trials. Among new users, the SRR for breast cancer was 
1.09 (0.98, 1.21), and there was no trend of increasing breast cancer 
risk with increasing duration of use of glargine (β = 0.04) (P = 0.52). 
Risk of breast cancer in a prospective cohort declined with increasing 
follow-up, from 1.99 (1.31, 2.03) with 2 years of follow-up, to 1.60 
(1.10 to 2.32) with 3 years, 1.50 (1.10 to 2.10) with 4 years and 1.18 
(0.84 to 1.66) with 5 years of follow-up. There is no reduction in risk 
of breast cancer associated with metformin use (SRR = 0.96 [95% 
CI, 0.85 to 1.08]) even for the longest duration of use (SRR = 0.94 
[95% CI, 0.81 to 1.09]).
An association between these 2 common diseases could have 
important implications for public health, with common risk factors 
